Switch theme
Sign up to access all valuation multiples
Nanogroup SA develops biotechnological and medical projects for diagnostics, therapy and rehabilitation of oncological patients. The company's portfolio includes Nano Velos, Nano Sanguis, and Nano Thea.
2013
46
Last FY Revenue $37K
Last FY EBITDA -$0.2M
$19.0M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, Nanogroup achieved revenue of $37K and an EBITDA of -$0.2M.
Nanogroup expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Nanogroup valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | $37K | XXX | XXX | XXX |
| Gross Profit | XXX | $12K | XXX | XXX | XXX |
| Gross Margin | XXX | 31% | XXX | XXX | XXX |
| EBITDA | XXX | -$0.2M | XXX | XXX | XXX |
| EBITDA Margin | XXX | -516% | XXX | XXX | XXX |
| EBIT | XXX | -$0.2M | XXX | XXX | XXX |
| EBIT Margin | XXX | -560% | XXX | XXX | XXX |
| Net Profit | XXX | -$0.2M | XXX | XXX | XXX |
| Net Margin | XXX | -601% | XXX | XXX | XXX |
| Net Debt | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Nanogroup's stock price is PLN 3 (or $1).
Nanogroup has current market cap of PLN 82.4M (or $21.9M), and EV of PLN 71.7M (or $19.0M).
See Nanogroup trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $19.0M | $21.9M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Nanogroup has market cap of $21.9M and EV of $19.0M.
Nanogroup's trades at 513.5x EV/Revenue multiple, and -99.5x EV/EBITDA.
Equity research analysts estimate Nanogroup's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Nanogroup's P/E ratio is not available.
See valuation multiples for Nanogroup and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $21.9M | XXX | $21.9M | XXX | XXX | XXX |
| EV (current) | $19.0M | XXX | $19.0M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 513.5x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -99.5x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | -91.6x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | -98.3x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -16.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialNanogroup's revenue per employee in the last FY averaged $1K, while opex per employee averaged $5K for the same period.
Nanogroup's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Nanogroup's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Nanogroup and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -516% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $1K | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $5K | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 592% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Nanogroup acquired XXX companies to date.
Last acquisition by Nanogroup was XXXXXXXX, XXXXX XXXXX XXXXXX . Nanogroup acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Nanogroup founded? | Nanogroup was founded in 2013. |
| Where is Nanogroup headquartered? | Nanogroup is headquartered in Poland. |
| How many employees does Nanogroup have? | As of today, Nanogroup has 46 employees. |
| Is Nanogroup publicy listed? | Yes, Nanogroup is a public company listed on WAR. |
| What is the stock symbol of Nanogroup? | Nanogroup trades under NNG ticker. |
| When did Nanogroup go public? | Nanogroup went public in 2017. |
| Who are competitors of Nanogroup? | Similar companies to Nanogroup include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Nanogroup? | Nanogroup's current market cap is $21.9M |
| Is Nanogroup profitable? | Yes, Nanogroup is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
